You can buy or sell NTGN and other stocks, options, ETFs, and crypto commission-free!
Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. Read More The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Renewable Energy Generation
Associated PressMar 11
Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and provided a business update. “2018 was a transformative year for Neon, highlighted by significant advances in applying our insights into neoantigen biology not only to our vaccine product candidates but also to our emerging cellular thera...
Associated PressFeb 28
Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the Ameri...
Expected May 2, Pre-Market